TCM Business Summary

TCM Biotech International Corp. (4169.TWO) operates as a vertically integrated biotechnology firm specializing in the research, development, manufacturing, and distribution of pharmaceuticals and medical devices. The company generates approximately 90% of its revenue through the sale of proprietary and licensed healthcare products, primarily targeting hospitals (90% of sales) and clinics (10%). Its business is segmented into liver disease therapeutics—focusing on Hepatitis B, non-alcoholic fatty liver disease (NAFLD), and liver fibrosis—and a growing medical device portfolio that includes osteoarthritis treatments, blood cell separators, and respiratory equipment. A key growth driver is its U101 pipeline, a non-antibiotic treatment for recurrent urinary tract infections. Within the Taiwanese biotech landscape, TCM competes directly with players such as PharmaEngine, Adimmune, EirGenix, and TaiMed Biologics, distinguishing itself through a hybrid model that funds high-risk R&D with stable cash flow from its established pharmaceutical distribution network. As of March 2026, the company is transitioning from the Taipei Exchange (TPEx) to a main board listing on the Taiwan Stock Exchange (TWSE). The leadership team is anchored by Chairman and Founder Hsu Huan-ching (Shining Hsu), who established the firm in 1998 following a successful career in pharmaceutical sales and management. The executive operations are led by General Manager and Director Dr. Ya-Chun Wang, a U.S.-educated PhD with over 20 years of experience in clinical trial planning and technology licensing. The company’s scientific strategy is heavily influenced by Chief Advisor Prof. Pei-Jer Chen, a globally recognized authority in liver disease and an academician at Academia Sinica. The Board of Directors includes industry veterans such as Yifang Xu and Jin-Ji Chen, supported by independent directors Zheng Hong Guo and Heng Yi Liu. Major institutional and individual backing is led by Chairman Hsu, who remains the largest shareholder with a 12.6% stake, alongside significant holdings from Green Partner Investments Limited and Shanzhu Enterprise Co., Ltd.